Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)Jan B. Vermorken, Paul M. Clément, John C. Krauss et al.|Annals of Oncology|2014Cited by 95